Literature DB >> 26328012

Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy.

Dana Kucerova1, Gabriel Doka2, Peter Kruzliak3, Katarina Turcekova2, Jana Kmecova2, Zuzana Brnoliakova4, Jan Kyselovic2, Uwe Kirchhefer5, Frank U Müller5, Peter Krenek2, Peter Boknik5, Jan Klimas2.   

Abstract

Calcium release channel on the sarcoplasmic reticulum of cardiomyocytes (ryanodine receptor type 2, RyR2) plays a critical role in the regulation of calcium and was identified as a crucial factor for development of chronic anthracycline cardiomyopathy. Its early stages are less well described although these determine the later development. Hence, we tested the effect of repeated, short-term anthracycline (daunorubicin) administration on cardiac performance, cardiomyocyte function and accompanied changes in calcium regulating proteins expression. Ten-twelve weeks old male Wistar rats were administered with 6 doses of daunorubicin (DAU, 3 mg/kg, i.p., every 48 h), controls (CON) received vehicle. Left ventricular function (left ventricular pressure, LVP; rate of pressure development, +dP/dt and decline, -dP/dt) was measured using left ventricular catheterization under tribromethanol anaesthesia (15 ml/kg b.w.). Cell shortening was measured in enzymatically isolated cardiomyocytes. The expressions of RyR2 and associated intracellular calcium regulating proteins, cytoskeletal proteins (alpha-actinin, alpha-tubul in) as well as oxidative stress regulating enzymes (gp91phox, MnSOD) were detected in ventricular tissue samples using immunoblotting. mRNA expressions of cardiac damage markers (Nppa and Nppb, atrial and brain natriuretic peptides; Myh6, Myh7 and Myh7b, myosin heavy chain alpha and beta) were detected using RT-PCR. Thiobarbituric acid reactive substances concentration was measured to estimate oxidative stress. DAU rats exhibited significantly depressed left ventricular features (LVP by 14%, +dP/dt by 36% and -dP/dt by 30%; for all P<0.05), in line with concomitant increase in Nppa and Nppb gene expressions (3.23- and 2.18-fold, for both P<0.05), and a 4.34-fold increase in Myh7 (P<0.05). Controversially, we observed increased cell shortening of isolated cardiac cells by 31% (p<0.05). DAU administration was associated with a twofold upregulation of RyR2 (P<0.05), but not of other examined Ca(2+) regulating proteins remained. In addition, we observed a significant reduction in alpha-tubulin (by 46% when compared to CON P<0.05). Indicators of oxidative injury were unaffected. In conclusion, unbalanced RyR2 overexpression plays a particular role in early development of daunorubicin cardiomyopathy characterized by discrepant in situ versus in vitro cardiac performance.

Entities:  

Keywords:  Calcium; daunorubicin cardiomyopathy; oxidative stress; ryanodine receptor 2 (RyR2)

Year:  2015        PMID: 26328012      PMCID: PMC4548320     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  55 in total

1.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

2.  Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy.

Authors:  Hana Cernecka; Katarina Ochodnicka-Mackovicova; Dana Kucerova; Jana Kmecova; Viera Nemcekova; Gabriel Doka; Jan Kyselovic; Peter Krenek; Peter Ochodnicky; Jan Klimas
Journal:  Eur J Pharmacol       Date:  2013-07-05       Impact factor: 4.432

3.  Persistent effects of doxorubicin on cardiac gene expression.

Authors:  R J Boucek; A Miracle; M Anderson; R Engelman; J Atkinson; D A Dodd
Journal:  J Mol Cell Cardiol       Date:  1999-08       Impact factor: 5.000

4.  Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

Authors:  Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Valeriano C Simbre; Seema L Shaikh; Suzanne M Mone; Richard D Gelber; Steven D Colan
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

Review 5.  The role of the cytoskeleton in heart failure.

Authors:  S Hein; S Kostin; A Heling; Y Maeno; J Schaper
Journal:  Cardiovasc Res       Date:  2000-01-14       Impact factor: 10.787

6.  Heart rate correction of the QT duration in rats.

Authors:  Jana Kmecova; Jan Klimas
Journal:  Eur J Pharmacol       Date:  2010-06-08       Impact factor: 4.432

7.  Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.

Authors:  Francesco Timolati; Daniel Ott; Laura Pentassuglia; Marie-Noëlle Giraud; Jean-Claude Perriard; Thomas M Suter; Christian Zuppinger
Journal:  J Mol Cell Cardiol       Date:  2006-09-26       Impact factor: 5.000

8.  Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes.

Authors:  Seon-Young Kim; Sang-Jin Kim; Byoung-Joo Kim; So-Young Rah; Sung Mo Chung; Mie-Jae Im; Uh-Hyun Kim
Journal:  Exp Mol Med       Date:  2006-10-31       Impact factor: 8.718

9.  Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity.

Authors:  J A Jackson; J P Reeves; K H Muntz; D Kruk; R A Prough; J T Willerson; L M Buja
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

10.  SCN5A mutations in Brugada syndrome are associated with increased cardiac dimensions and reduced contractility.

Authors:  Frans van Hoorn; Maria E Campian; Anje Spijkerboer; Marieke T Blom; R Nils Planken; Albert C van Rossum; Jacques M T de Bakker; Arthur A M Wilde; Maarten Groenink; Hanno L Tan
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

View more
  6 in total

1.  Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy.

Authors:  Gabriel Doka; Eva Malikova; Kristina Galkova; Giampiero La Rocca; Peter Kruzliak; Mariusz Adamek; Luis Rodrigo; Peter Krenek; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2017-03-16       Impact factor: 3.396

2.  Verapamil suppresses cardiac alternans and ventricular arrhythmias in acute myocardial ischemia via ryanodine receptor inhibition.

Authors:  Yu-Lei Deng; Jun-Yan Zhao; Ji-Hua Yao; Qiang Tang; Le Zhang; Hong-Lian Zhou; Cun-Tai Zhang; Jia-Gao Lv; Xiao-Qing Quan
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

3.  The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity.

Authors:  Minttu Mattila; Mirva Söderström; Liisa Ailanen; Eriika Savontaus; Mikko Savontaus
Journal:  Cardiovasc Toxicol       Date:  2020-06       Impact factor: 3.231

4.  Isolated downregulation of HCN2 in ventricles of rats with streptozotocin-induced diabetic cardiomyopathy.

Authors:  Katarina Hadova; Eva Kralova; Gabriel Doka; Lenka Bies Pivackova; Zuzana Kmecova; Peter Krenek; Jan Klimas
Journal:  BMC Cardiovasc Disord       Date:  2021-03-02       Impact factor: 2.298

5.  Epigallocatechin-3-gallate improves cardiac hypertrophy and short-term memory deficits in a Williams-Beuren syndrome mouse model.

Authors:  Paula Ortiz-Romero; Cristina Borralleras; Mònica Bosch-Morató; Biuse Guivernau; Guillermo Albericio; Francisco J Muñoz; Luis A Pérez-Jurado; Victoria Campuzano
Journal:  PLoS One       Date:  2018-03-19       Impact factor: 3.240

Review 6.  Genomic Insights into Cardiomyopathies: A Comparative Cross-Species Review.

Authors:  Siobhan Simpson; Paul Rutland; Catrin Sian Rutland
Journal:  Vet Sci       Date:  2017-03-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.